Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonesupport Holding ABBOEUF 81 Debt-to-EBITDA is 0.03 as of Jun. 2026. GuruFocus rates BOEUF with a GF Score™ of 81/100 and a GF Value™ of $42.84 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Bonesupport Holding AB ranks better than 96.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bonesupport Holding AB's Debt-to-EBITDA or its related term are showing as below:
BOEUF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.14 Med: -0.12 Max: 0.6
Current: 0.03
During the past 12 years, the highest Debt-to-EBITDA Ratio of Bonesupport Holding AB was 0.60. The lowest was -1.14. And the median was -0.12.
BOEUF's Debt-to-EBITDA is ranked better than 96.79% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs BOEUF: 0.03
Bonesupport Holding AB (OTCPK:BOEUF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bonesupport Holding AB Debt-to-EBITDA Related Terms
Bonesupport Holding AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bonesupport Holding AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOEUF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bonesupport Holding AB (BOEUF) has a Debt-to-EBITDA of 0.03 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonesupport Holding AB. According to the industry distribution chart, Bonesupport Holding AB ranks #15 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 3.2%.
Is Bonesupport Holding AB's Debt-to-EBITDA too high?
Bonesupport Holding AB's current Debt-to-EBITDA is 0.03. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Bonesupport Holding AB's value of 0.03 is 98.1% below this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #15 out of 467 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonesupport Holding AB has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #15 out of 467 companies for Debt-to-EBITDA. This places Bonesupport Holding AB in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.57. Bonesupport Holding AB's value of 0.03 is 98.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current Debt-to-EBITDA of 0.03 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonesupport Holding AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current Debt-to-EBITDA is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (BOEUF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.84, compared to a current price of $21.40 — trading 50% below its estimated fair value. The current Debt-to-EBITDA is 0.03 and 98.1% below the Medical Devices & Instruments industry median of 1.57. Bonesupport Holding AB's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bonesupport Holding AB (BOEUF), the current Debt-to-EBITDA is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (BOEUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of $21.40 is trading 50% below its estimated GF Value™ of $42.84.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for BOEUF:
Debt-to-EBITDA: 0.03
GF Value™: $42.84 vs. price of $21.40 (50% below fair value)
Industry Position: 98.1% below the Medical Devices & Instruments median (#15 of 467)
No single metric tells the full story. See the BOEUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
81GF Score
Get the complete analysis for BOEUF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOEUF has been successfully added to your 
